New research suggests that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who end traditional lifestyle regimens.
Published data in a prominent health publication demonstrates that while overweight people can lose about a fifth of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using these medications must be cognizant of the potential of quick rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to pre-treatment mass within about a year and a half.
Weighing Approaches
The study, which reviewed 37 of trials involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with older methods.
The team emphasize that individuals who lose weight through lifestyle changes alone usually see a more gradual creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Fast Regain
Nutrition scientists propose the mode of action of the drugs accounts for the amplified weight return.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication leads to appetite is uncontrolled, making excessive eating far more likely."
An Ongoing Disease?
Medical guidelines recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals contend that, due to the significant potential of weight regain, the therapy should be considered life-long.
This opinion is reinforced by pharmaceutical companies, who say that the findings "emphasize the long-term nature of obesity," comparing it to managing diseases like hypertension.
User Experiences
Users who have come off the jabs explain a intense resurgence of appetite.
"I experienced something that goes on and I was suddenly extremely hungry," recalled a patient.
This difficulty is compounded if users have not established lasting dietary or behavioural modifications during therapy.
Growing Use
Survey data suggest that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and long-term success hinges on ongoing lifestyle support.
